Fibrocell Science, Inc. (FCSC) Reaches $2.50 After 5.00% Down Move; Top Ships (TOPS) Shorts Up By 11.54%

June 11, 2018 - By Jacob Smith

Fibrocell Science, Inc. (NASDAQ:FCSC) Logo

Top Ships Inc (NASDAQ:TOPS) had an increase of 11.54% in short interest. TOPS’s SI was 1.31M shares in June as released by FINRA. Its up 11.54% from 1.17 million shares previously. With 4.17M avg volume, 0 days are for Top Ships Inc (NASDAQ:TOPS)’s short sellers to cover TOPS’s short positions. The stock decreased 0.93% or $0.01 during the last trading session, reaching $1.06. About 1.00 million shares traded. Top Ships Inc. (NASDAQ:TOPS) has declined 99.96% since June 11, 2017 and is downtrending. It has underperformed by 112.53% the S&P500. Some Historical TOPS News: ; 03/05/2018 – TOP Ships Inc. Announces Extension of Time Charter of M/T Eco Fleet; 03/05/2018 – TOP SHIPS INC – HAS EXTENDED FIRM PERIOD OF TIME CHARTER OF M/T ECO FLEET WITH BP SHIPPING LIMITED FOR SIX MONTHS; 11/04/2018 – TOP Ships Inc. Announces Compliance With NASDAQ Minimum Bid Price Requirement; 11/04/2018 – TOP Ships Regains Compliance With Nasdaq Minimum Bid Price Requirement; 22/03/2018 TOP Ships Announces Change in Its Capital Raising Corporate Strategy and Other Corporate Developments; 22/03/2018 – TOP Ships Effecting a 1-For-10 Reverse Stk Split; 30/03/2018 – Top Ships – Annual Report 20F Summary Looks Favorable For Investors; 30/04/2018 – TOP Ships Inc. Announces Successful Completion of Sea Trials and Delivery Date of M/T Eco Palm Springs; 29/05/2018 – TOP Ships Inc. Announces Delivery and Charter Employment of M/T Eco Palm Springs; 30/03/2018 – TOP Ships Inc. Announces Filing of 2017 Annual Report on Form 20-F

The stock of Fibrocell Science, Inc. (NASDAQ:FCSC) is a huge mover today! The stock decreased 1.96% or $0.05 during the last trading session, reaching $2.5. About 362,806 shares traded. Fibrocell Science, Inc. (NASDAQ:FCSC) has declined 76.28% since June 11, 2017 and is downtrending. It has underperformed by 88.85% the S&P500. Some Historical FCSC News: ; 29/05/2018 – FIBROCELL SCIENCE – INTENDS TO USE NET PROCEEDS FROM OFFERING FOR CONTINUED CLINICAL AND PRE-CLINICAL DEVELOPMENT OF FCX-007 AND FCX-013; 21/05/2018 – Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic; 21/05/2018 – FIBROCELL SCIENCE INC – FCX-007 WELL-TOLERATED UP TO 52 WEEKS POST-ADMINISTRATION; 18/04/2018 Fibrocell Science to Continue Advancing Phase 1/2 Clinical Trial of FCX-007; 21/05/2018 – FIBROCELL REPORTS ON INTERIM RESULTS AND PROGRESS OF PHASE 1/2 CLINICAL TRIAL OF FCX-007 GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA; 24/05/2018 – Fibrocell Announces One-for-Five Reverse Stk SplitThe move comes after 7 months negative chart setup for the $19.27M company. It was reported on Jun, 11 by We have $2.38 PT which if reached, will make NASDAQ:FCSC worth $963,700 less.

Top Ships Inc. provides seaborne transportation services worldwide. The company has market cap of $17.99 million. It owns and operates medium range tanker vessels that transport crude oil, petroleum products, and bulk liquid chemicals. It currently has negative earnings. The firm transports petroleum products and crude oil for the oil industry.

More recent Top Ships Inc. (NASDAQ:TOPS) news were published by: which released: “Mid-Day Market Update: Crude Oil Up Over 1.5%; Conn’s Shares Rise Following Upbeat Results” on June 07, 2018. Also published the news titled: “TOP Ships Inc. Announces Interest Rate Swap Agreements” on June 05, 2018.‘s news article titled: “Aegean Marine: Did ‘The Tiger’ Leave Any Flesh On Its Prey?” with publication date: June 07, 2018 was also an interesting one.

More notable recent Fibrocell Science, Inc. (NASDAQ:FCSC) news were published by: which released: “Fibrocell Announces Closing of $6.0 Million Registered Direct Offering” on May 31, 2018, also with their article: “Fibrocell Announces One-for-Five Reverse Stock Split” published on May 24, 2018, published: “Fibrocell Announces Oral Presentation at 7th International Investigative Dermatology Meeting” on May 16, 2018. More interesting news about Fibrocell Science, Inc. (NASDAQ:FCSC) were released by: and their article: “Mid-Afternoon Market Update: Crude Oil Down 2.5%; American Woodmark Shares Spike Higher” published on May 29, 2018 as well as‘s news article titled: “Mid-Morning Market Update: Markets Open Lower; Booz Allen Hamilton Profit Beats Estimates” with publication date: May 29, 2018.

Analysts await Fibrocell Science, Inc. (NASDAQ:FCSC) to report earnings on August, 8. They expect $-0.55 earnings per share, up 64.52% or $1.00 from last year’s $-1.55 per share. After $-0.55 actual earnings per share reported by Fibrocell Science, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Among 6 analysts covering Fibrocell Science (NASDAQ:FCSC), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Fibrocell Science had 14 analyst reports since September 28, 2015 according to SRatingsIntel. H.C. Wainwright maintained it with “Buy” rating and $7.6 target in Thursday, October 5 report. The firm earned “Buy” rating on Tuesday, December 22 by TH Capital. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, March 6. The stock of Fibrocell Science, Inc. (NASDAQ:FCSC) earned “Neutral” rating by Wedbush on Monday, September 28. The firm has “Buy” rating given on Friday, June 9 by H.C. Wainwright. The firm has “Buy” rating given on Wednesday, August 9 by H.C. Wainwright. As per Tuesday, December 22, the company rating was initiated by Roth Capital. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, September 26. The stock of Fibrocell Science, Inc. (NASDAQ:FCSC) has “Buy” rating given on Tuesday, January 30 by H.C. Wainwright. The stock has “Buy” rating by H.C. Wainwright on Monday, March 19.

Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints in the United States. The company has market cap of $19.27 million. The company's gene-therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development stage for the treatment of linear scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It currently has negative earnings. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints.

Fibrocell Science, Inc. (NASDAQ:FCSC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: